(January 20 08:57) Forbes.com
Two large U.S.-based drug companies - AbbVie and Eli Lilly - have now exited the voluntary drug price agreement, citing the “punitive” system of revenue clawbacks, which has risen to 26.5% of branded sales in 2022. And, AbbVie and Lilly aren’t the only companies complaining about the levies.
You can find the original article
here